Details of the Drug Combination

General Information of Drug Combination (ID: DCSWTMN)

• Drug Combination Name: Sertraline + Haloperidol
• Indication: Affective Disorders; Status: Phase 1 [1]
• Component Drugs:
  Sertraline (DM0FB1J): Small molecular drug
  Haloperidol (DM96SE0): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Sertraline

Disease Entry	ICD 11	Status	REF
Coronary heart disease	BA80.Z	Approved	[2]
Depression	6A70-6A7Z	Approved	[3]
Epilepsy	8A60-8A68	Approved	[2]
Obsessive compulsive disorder	6B20	Approved	[2]
Panic disorder	6B01	Approved	[2]
Post-traumatic stress disorder	6B40	Approved	[2]

Sertraline Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[11]

Sertraline Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

Sertraline Interacts with 7 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[13]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[14]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[15]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Metabolism	[16]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[17]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Metabolism	[18]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[18]

Sertraline Interacts with 88 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Decreases Activity	[19]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Increases ADR	[20]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Decreases Methylation	[21]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Activity	[22]
Phytanoyl-CoA dioxygenase, peroxisomal (PHYH)	OTUG4BWA	PAHX_HUMAN	Increases Expression	[7]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Increases Expression	[7]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Increases Expression	[7]
Serine protease hepsin (HPN)	OT7QNA61	HEPS_HUMAN	Increases Expression	[7]
Fatty acid-binding protein, liver (FABP1)	OTR34ETM	FABPL_HUMAN	Increases Expression	[7]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Increases Expression	[7]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)	OT2HZK5M	GTR3_HUMAN	Decreases Expression	[7]
Lanosterol synthase (LSS)	OT9W2SFH	LSS_HUMAN	Increases Expression	[7]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Increases Expression	[7]
Transgelin (TAGLN)	OTAEZ0KP	TAGL_HUMAN	Decreases Expression	[7]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Increases Expression	[7]
Nuclear receptor subfamily 0 group B member 2 (NR0B2)	OT7UVICX	NR0B2_HUMAN	Increases Expression	[7]
Lysophospholipase D GDPD3 (GDPD3)	OTOHM9QM	GDPD3_HUMAN	Increases Expression	[7]
Fibronectin type III domain-containing protein 4 (FNDC4)	OTOQK0WK	FNDC4_HUMAN	Increases Expression	[7]
Protein DEPP1 (DEPP1)	OTB36PHJ	DEPP1_HUMAN	Increases Expression	[7]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Expression	[23]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Expression	[23]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Decreases Activity	[24]
Mitogen-activated protein kinase kinase kinase 13 (MAP3K13)	OTS93BTX	M3K13_HUMAN	Increases Expression	[8]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B)	OTL9I7LO	GA45B_HUMAN	Increases Expression	[8]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1)	OTY9R6FZ	ERN1_HUMAN	Increases Expression	[8]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Increases Expression	[8]
Dual specificity protein phosphatase 14 (DUSP14)	OTGODFCR	DUS14_HUMAN	Increases Expression	[8]
Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4)	OTBMJUOC	M4K4_HUMAN	Decreases Expression	[8]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Expression	[8]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Increases Expression	[8]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Increases Expression	[8]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases Expression	[25]
Alpha-crystallin A chain (CRYAA)	OTSN7JUR	CRYAA_HUMAN	Increases Expression	[8]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Affects Binding	[26]
Platelet basic protein (PPBP)	OT1FHGQS	CXCL7_HUMAN	Decreases Expression	[27]
Platelet factor 4 (PF4)	OTEMJU68	PLF4_HUMAN	Decreases Expression	[9]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Increases Phosphorylation	[8]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Expression	[8]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Increases Expression	[28]
Monocyte differentiation antigen CD14 (CD14)	OT83GJ47	CD14_HUMAN	Decreases Expression	[8]
Heat shock 70 kDa protein 1A (HSPA1A)	OTKGIE76	HS71A_HUMAN	Increases Expression	[8]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[25]
Heat shock cognate 71 kDa protein (HSPA8)	OTJI2RCI	HSP7C_HUMAN	Decreases Expression	[8]
Cyclic AMP-dependent transcription factor ATF-2 (ATF2)	OTNIZPEA	ATF2_HUMAN	Increases Expression	[8]
P-selectin (SELP)	OTWR90PK	LYAM3_HUMAN	Decreases Expression	[27]
Platelet endothelial cell adhesion molecule (PECAM1)	OTXOM4D9	PECA1_HUMAN	Decreases Expression	[9]
E-selectin (SELE)	OT33RZWY	LYAM2_HUMAN	Decreases Expression	[27]
Stathmin (STMN1)	OTDJ4RV0	STMN1_HUMAN	Decreases Expression	[8]
Heat shock 70 kDa protein 6 (HSPA6)	OTH4S7WB	HSP76_HUMAN	Increases Expression	[8]
Transcription factor JunD (JUND)	OTNKACJD	JUND_HUMAN	Increases Expression	[8]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[8]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Increases Expression	[8]
Ribosomal protein S6 kinase beta-1 (RPS6KB1)	OTAELNGX	KS6B1_HUMAN	Decreases Phosphorylation	[10]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[8]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[25]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[25]
Dual specificity protein phosphatase 1 (DUSP1)	OTN6BR75	DUS1_HUMAN	Increases Expression	[8]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[8]
Mitogen-activated protein kinase kinase kinase 8 (MAP3K8)	OTOZTA1F	M3K8_HUMAN	Increases Expression	[8]
Serine/threonine-protein kinase mTOR (MTOR)	OTHH8KU7	MTOR_HUMAN	Decreases Phosphorylation	[10]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[8]
Translocon-associated protein subunit beta (SSR2)	OTQJSL7M	SSRB_HUMAN	Increases Expression	[8]
Caspase-4 (CASP4)	OTVQTV1L	CASP4_HUMAN	Increases Cleavage	[8]
Ribosomal protein S6 kinase alpha-3 (RPS6KA3)	OTYJNNMD	KS6A3_HUMAN	Decreases Expression	[8]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[8]
Protein transport protein Sec61 subunit gamma (SEC61G)	OT7MJRXY	SC61G_HUMAN	Decreases Expression	[8]
E3 ubiquitin-protein ligase RBX1 (RBX1)	OTYA1UIO	RBX1_HUMAN	Decreases Expression	[8]
S-phase kinase-associated protein 1 (SKP1)	OT5BPAZ4	SKP1_HUMAN	Decreases Expression	[8]
Nuclear factor NF-kappa-B p100 subunit (NFKB2)	OTS231V7	NFKB2_HUMAN	Increases Expression	[8]
Transcription factor RelB (RELB)	OTU3QYEF	RELB_HUMAN	Increases Expression	[8]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[25]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[29]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Increases Phosphorylation	[10]
Dual specificity protein phosphatase 8 (DUSP8)	OTPLMPG9	DUS8_HUMAN	Increases Expression	[8]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Increases Expression	[10]
Cullin-1 (CUL1)	OTXPE1UZ	CUL1_HUMAN	Decreases Expression	[8]
Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (HERPUD1)	OT9EROL6	HERP1_HUMAN	Increases Expression	[8]
Serine/threonine-protein kinase STK11 (STK11)	OT1YZSP3	STK11_HUMAN	Increases Phosphorylation	[10]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Expression	[8]
E3 ubiquitin-protein ligase synoviolin (SYVN1)	OTZ4ZJP5	SYVN1_HUMAN	Increases Expression	[8]
Dual specificity protein phosphatase 16 (DUSP16)	OTK7S078	DUS16_HUMAN	Increases Expression	[8]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)	OTUYHB84	MLP3B_HUMAN	Increases Lipidation	[10]
DnaJ homolog subfamily C member 5 (DNAJC5)	OTCZDXAL	DNJC5_HUMAN	Increases Expression	[30]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3)	OT0DZGY4	E2AK3_HUMAN	Increases Expression	[8]
Serine/threonine-protein kinase TAO2 (TAOK2)	OTNUMOZ1	TAOK2_HUMAN	Increases Expression	[8]
C-Jun-amino-terminal kinase-interacting protein 3 (MAPK8IP3)	OT0X8ACY	JIP3_HUMAN	Increases Expression	[8]
Dual specificity protein phosphatase 10 (DUSP10)	OTNG467B	DUS10_HUMAN	Increases Expression	[8]
Sodium-dependent serotonin transporter (SLC6A4)	OT6FGDLW	SC6A4_HUMAN	Increases Response To Substance	[31]

Indication(s) of Haloperidol

Disease Entry	ICD 11	Status	REF
Delirium	N.A.	Approved	[4]
Nausea	MD90	Approved	[4]
Psychotic disorder	6A20-6A25	Approved	[4]
Schizophrenia	6A20	Approved	[5]
Vomiting	MD90	Approved	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[6]
Tourette syndrome	8A05.00	Investigative	[4]

Haloperidol Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[35]
HUMAN opioid receptor sigma 1 (OPRS1)	TTTPE1L	SGMR1_HUMAN	Modulator	[36]
HUMAN sigma intracellular receptor 2 (TMEM97)	TTIS0R2	SGMR2_HUMAN	Modulator	[36]

Haloperidol Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[37]

Haloperidol Interacts with 9 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[38]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[39]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Metabolism	[39]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[40]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[38]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[41]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[39]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[39]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Metabolism	[42]

Haloperidol Interacts with 129 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Affects Response To Substance	[43]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Expression	[44]
D(1A) dopamine receptor (DRD1)	OTLZPBT7	DRD1_HUMAN	Affects Activity	[45]
D(4) dopamine receptor (DRD4)	OTAJTO7N	DRD4_HUMAN	Affects Activity	[45]
Brain-derived neurotrophic factor (BDNF)	OTLGH7EW	BDNF_HUMAN	Increases Expression	[46]
D(3) dopamine receptor (DRD3)	OT0OFFKB	DRD3_HUMAN	Affects Binding	[47]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Increases ADR	[20]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases ADR	[20]
G protein-activated inward rectifier potassium channel 1 (KCNJ3)	OTHQG16J	KCNJ3_HUMAN	Increases ADR	[20]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Decreases Expression	[44]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Expression	[44]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Increases Expression	[48]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Increases Expression	[48]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[48]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)	OTCO26FV	HMCS1_HUMAN	Increases Expression	[48]
Lathosterol oxidase (SC5D)	OT41KMW4	SC5D_HUMAN	Increases Expression	[49]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Increases Expression	[49]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Increases Expression	[32]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Increases Expression	[32]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Decreases Expression	[32]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Increases Expression	[32]
Transgelin (TAGLN)	OTAEZ0KP	TAGL_HUMAN	Decreases Expression	[32]
Nuclear receptor subfamily 0 group B member 2 (NR0B2)	OT7UVICX	NR0B2_HUMAN	Increases Expression	[32]
Lysophospholipase D GDPD3 (GDPD3)	OTOHM9QM	GDPD3_HUMAN	Increases Expression	[32]
Fibronectin type III domain-containing protein 4 (FNDC4)	OTOQK0WK	FNDC4_HUMAN	Increases Expression	[32]
Protein DEPP1 (DEPP1)	OTB36PHJ	DEPP1_HUMAN	Increases Expression	[32]
AP-3 complex subunit beta-1 (AP3B1)	OTYTIH5Q	AP3B1_HUMAN	Increases Expression	[33]
Importin subunit alpha-3 (KPNA4)	OTP0EX18	IMA3_HUMAN	Increases Expression	[33]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2)	OT8L6EGI	BCAT2_HUMAN	Decreases Expression	[33]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Increases Expression	[50]
Period circadian protein homolog 1 (PER1)	OTVQF3WX	PER1_HUMAN	Increases Expression	[51]
Kinesin heavy chain isoform 5C (KIF5C)	OT35570Y	KIF5C_HUMAN	Decreases Expression	[33]
Copine-3 (CPNE3)	OTCR3WG2	CPNE3_HUMAN	Decreases Expression	[33]
CCR4-NOT transcription complex subunit 3 (CNOT3)	OT4D5Z9L	CNOT3_HUMAN	Decreases Expression	[33]
Pyridoxal phosphate homeostasis protein (PLPBP)	OT9DZ8P6	PLPHP_HUMAN	Increases Expression	[33]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Increases Expression	[52]
Fatty acid-binding protein, heart (FABP3)	OT562DA1	FABPH_HUMAN	Increases Expression	[33]
Prothymosin alpha (PTMA)	OT2W4T1M	PTMA_HUMAN	Increases Expression	[33]
Corticoliberin (CRH)	OT2MOC4T	CRF_HUMAN	Decreases Expression	[53]
Profilin-1 (PFN1)	OTHTGA1H	PROF1_HUMAN	Increases Expression	[33]
Signal recognition particle receptor subunit alpha (SRPRA)	OT5NMYTY	SRPRA_HUMAN	Decreases Expression	[33]
Stromelysin-2 (MMP10)	OTJDWW8Q	MMP10_HUMAN	Decreases Expression	[33]
Glycogen phosphorylase, muscle form (PYGM)	OTWLVWTV	PYGM_HUMAN	Decreases Expression	[33]
Histidine--tRNA ligase, cytoplasmic (HARS1)	OTHOEOTS	HARS1_HUMAN	Increases Expression	[33]
Plastin-3 (PLS3)	OTYBM4PK	PLST_HUMAN	Decreases Expression	[33]
Glial fibrillary acidic protein (GFAP)	OTQ01ZAS	GFAP_HUMAN	Decreases Expression	[33]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4)	OTJZG0LD	GLUT4_HUMAN	Increases Expression	[54]
Ezrin (EZR)	OTHBPF1Z	EZRI_HUMAN	Decreases Expression	[33]
V-type proton ATPase subunit B, kidney isoform (ATP6V1B1)	OT8FQ7MN	VATB1_HUMAN	Decreases Expression	[33]
Probable ATP-dependent RNA helicase DDX5 (DDX5)	OTLS124U	DDX5_HUMAN	Decreases Expression	[33]
Vascular endothelial growth factor receptor 1 (FLT1)	OTT0OGYS	VGFR1_HUMAN	Decreases Expression	[33]
Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PCMT1)	OTGYVSGU	PIMT_HUMAN	Decreases Expression	[33]
Cofilin-1 (CFL1)	OTT6D5MH	COF1_HUMAN	Increases Expression	[33]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Decreases Expression	[33]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Affects Binding	[55]
General transcription factor IIE subunit 1 (GTF2E1)	OTAG9V0I	T2EA_HUMAN	Decreases Expression	[33]
Stress-induced-phosphoprotein 1 (STIP1)	OT7TXLOX	STIP1_HUMAN	Decreases Expression	[33]
Catenin alpha-1 (CTNNA1)	OTFC725Z	CTNA1_HUMAN	Decreases Expression	[33]
Radixin (RDX)	OTNSYUN6	RADI_HUMAN	Decreases Expression	[33]
Vascular endothelial growth factor receptor 2 (KDR)	OT15797V	VGFR2_HUMAN	Increases Expression	[33]
Transgelin-2 (TAGLN2)	OTUXZGDQ	TAGL2_HUMAN	Decreases Expression	[33]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA)	OTIOLNHE	LICH_HUMAN	Increases Expression	[33]
Pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1)	OTNBHULA	PACR_HUMAN	Affects Expression	[34]
Small ribosomal subunit protein eS27 (RPS27)	OTFXKY7P	RS27_HUMAN	Increases Expression	[33]
Cell surface glycoprotein MUC18 (MCAM)	OTT8XKGE	MUC18_HUMAN	Increases Expression	[33]
Vesicle-fusing ATPase (NSF)	OTKRJ2ZT	NSF_HUMAN	Decreases Expression	[33]
Serine--tRNA ligase, cytoplasmic (SARS1)	OTFKXQ1O	SYSC_HUMAN	Decreases Expression	[33]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL)	OT50L4XB	ACADV_HUMAN	Decreases Expression	[33]
Peroxisomal multifunctional enzyme type 2 (HSD17B4)	OT8733D7	DHB4_HUMAN	Decreases Expression	[33]
Delta-1-pyrroline-5-carboxylate synthase (ALDH18A1)	OT6W40XU	P5CS_HUMAN	Decreases Expression	[33]
Heterogeneous nuclear ribonucleoprotein K (HNRNPK)	OTNPRM8U	HNRPK_HUMAN	Decreases Expression	[33]
Small ribosomal subunit protein uS9 (RPS16)	OTVGZOB5	RS16_HUMAN	Decreases Expression	[33]
Large ribosomal subunit protein eL30 (RPL30)	OTLQVY1Z	RL30_HUMAN	Increases Expression	[33]
Microtubule-associated protein 1A (MAP1A)	OTHO8K43	MAP1A_HUMAN	Decreases Expression	[33]
Large ribosomal subunit protein eL19 (RPL19)	OT33LM66	RL19_HUMAN	Decreases Expression	[33]
Transcriptional activator protein Pur-alpha (PURA)	OT975ELW	PURA_HUMAN	Increases Expression	[33]
Protein Dr1 (DR1)	OTR081M4	NC2B_HUMAN	Decreases Expression	[33]
Synaptic vesicular amine transporter (SLC18A2)	OTUOMMM6	VMAT2_HUMAN	Affects Binding	[56]
Mitochondrial-processing peptidase subunit alpha (PMPCA)	OT5X1G9Q	MPPA_HUMAN	Increases Expression	[33]
Aspartyl/asparaginyl beta-hydroxylase (ASPH)	OT3KGDEE	ASPH_HUMAN	Increases Expression	[33]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[57]
Translation initiation factor eIF2B subunit epsilon (EIF2B5)	OTV3R4RB	EI2BE_HUMAN	Increases Expression	[33]
Transcription intermediary factor 1-beta (TRIM28)	OTE38OBF	TIF1B_HUMAN	Decreases Expression	[33]
Condensin complex subunit 2 (NCAPH)	OTXOS97C	CND2_HUMAN	Decreases Expression	[33]
Inorganic pyrophosphatase (PPA1)	OTHZK1QB	IPYR_HUMAN	Increases Expression	[33]
Reticulocalbin-1 (RCN1)	OT3JBGAG	RCN1_HUMAN	Decreases Expression	[33]
Splicing factor 3B subunit 4 (SF3B4)	OTGB9OR9	SF3B4_HUMAN	Decreases Expression	[33]
Disks large homolog 2 (DLG2)	OTQ3BD8U	DLG2_HUMAN	Increases Expression	[33]
Striated muscle preferentially expressed protein kinase (SPEG)	OTQXWJR4	SPEG_HUMAN	Increases Expression	[33]
Cryptochrome-1 (CRY1)	OTTGAJT0	CRY1_HUMAN	Decreases Expression	[51]
Histone H2A type 2-C (H2AC20)	OTEIVLM1	H2A2C_HUMAN	Increases Expression	[33]
Tau-tubulin kinase 1 (TTBK1)	OTYW316L	TTBK1_HUMAN	Increases Expression	[33]
Coiled-coil domain-containing protein 121 (CCDC121)	OTWZ4FTT	CC121_HUMAN	Increases Expression	[33]
Nucleoporin p54 (NUP54)	OTHOIRMG	NUP54_HUMAN	Decreases Expression	[33]
Retinol dehydrogenase 11 (RDH11)	OTIND43N	RDH11_HUMAN	Decreases Expression	[33]
Dynein axonemal heavy chain 3 (DNAH3)	OTD2JOKM	DYH3_HUMAN	Increases Expression	[33]
Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 (DHX38)	OTBVB3W5	PRP16_HUMAN	Decreases Expression	[33]
Small ribosomal subunit protein mS31 (MRPS31)	OTB0OBWK	RT31_HUMAN	Increases Expression	[33]
AP-2 complex subunit mu (AP2M1)	OTQCOSFN	AP2M1_HUMAN	Increases Expression	[33]
Probable ATP-dependent RNA helicase DDX27 (DDX27)	OT64NCZ6	DDX27_HUMAN	Increases Expression	[33]
PDZ and LIM domain protein 5 (PDLIM5)	OTLQVV22	PDLI5_HUMAN	Decreases Expression	[33]
Kremen protein 1 (KREMEN1)	OTGJFSAC	KREM1_HUMAN	Increases Expression	[33]
KH domain-containing RNA-binding protein QKI (QKI)	OTTAUGLB	QKI_HUMAN	Increases Expression	[58]
Transcriptional regulator protein Pur-beta (PURB)	OTCDDKYB	PURB_HUMAN	Decreases Expression	[33]
Melanin-concentrating hormone receptor 1 (MCHR1)	OTT57EOE	MCHR1_HUMAN	Affects Binding	[59]
Transmembrane 9 superfamily member 2 (TM9SF2)	OTA0C202	TM9S2_HUMAN	Decreases Expression	[33]
COP9 signalosome complex subunit 4 (COPS4)	OTNK2KS1	CSN4_HUMAN	Decreases Expression	[33]
Histone H2A.J (H2AJ)	OTVA4XTW	H2AJ_HUMAN	Increases Expression	[33]
MKI67 FHA domain-interacting nucleolar phosphoprotein (NIFK)	OT20GHN3	MK67I_HUMAN	Decreases Expression	[33]
ATP-dependent DNA/RNA helicase DHX36 (DHX36)	OT8IGL9Y	DHX36_HUMAN	Decreases Expression	[33]
tRNA:m(4)X modification enzyme TRM13 homolog (TRMT13)	OT2H0MCE	TRM13_HUMAN	Decreases Expression	[33]
Tropomodulin-3 (TMOD3)	OTQPNSTH	TMOD3_HUMAN	Decreases Expression	[33]
Endoplasmic reticulum aminopeptidase 1 (ERAP1)	OT72S99B	ERAP1_HUMAN	Decreases Expression	[33]
Ribosome-binding protein 1 (RRBP1)	OT4ZTPTM	RRBP1_HUMAN	Decreases Expression	[33]
DnaJ homolog subfamily B member 11 (DNAJB11)	OTDDK2SY	DJB11_HUMAN	Increases Expression	[33]
Translocation protein SEC63 homolog (SEC63)	OT1ICPMK	SEC63_HUMAN	Increases Expression	[33]
Cysteine and histidine-rich domain-containing protein 1 (CHORDC1)	OT3W6F1U	CHRD1_HUMAN	Increases Expression	[33]
Unconventional myosin-Vb (MYO5B)	OTCKL3W3	MYO5B_HUMAN	Decreases Expression	[33]
Pre-mRNA-processing factor 19 (PRPF19)	OTQ1STV3	PRP19_HUMAN	Increases Expression	[33]
E3 ubiquitin-protein ligase PDZRN3 (PDZRN3)	OTQ891OS	PZRN3_HUMAN	Decreases Expression	[33]
DNA-binding protein SATB2 (SATB2)	OT2W80XC	SATB2_HUMAN	Decreases Expression	[33]
TRPM8 channel-associated factor 1 (TCAF1)	OTSQQ37P	TCAF1_HUMAN	Decreases Expression	[33]
Talin-2 (TLN2)	OT10QQBC	TLN2_HUMAN	Decreases Expression	[33]
Mitogen-activated protein kinase 14 (MAPK14)	OT5TCO3O	MK14_HUMAN	Increases ADR	[20]
Sodium-dependent serotonin transporter (SLC6A4)	OT6FGDLW	SC6A4_HUMAN	Increases ADR	[20]
Dysbindin (DTNBP1)	OT9UQT2S	DTBP1_HUMAN	Increases Response To Substance	[60]
NADH-ubiquinone oxidoreductase chain 1 (ND1)	OTCLGIXV	NU1M_HUMAN	Increases ADR	[20]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases ADR	[20]
Synaptosomal-associated protein 25 (SNAP25)	OTUIQ81Q	SNP25_HUMAN	Affects Response To Substance	[61]

References

• [1] ClinicalTrials.gov (NCT00340379) Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
• [2] Sertraline FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4798).
• [4] Haloperidol FDA Label
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 86).
• [6] Sigma-1Rs are upregulated via PERK/eIF2/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25.
• [7] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [8] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [9] Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry. 2005 Jun;162(6):1165-70. doi: 10.1176/appi.ajp.162.6.1165.
• [10] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [11] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [12] Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
• [13] New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
• [14] The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001 Spring;7(1):1-24.
• [15] Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12.
• [16] PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166181117)
• [17] Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
• [18] Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
• [19] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [20] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [21] Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Jul;70(1):42-7.
• [22] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [23] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [24] Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
• [25] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [26] Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
• [27] Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
• [28] Impact of selective serotonin reuptake inhibitors on neural crest stem cell formation. Toxicol Lett. 2017 Nov 5;281:20-25. doi: 10.1016/j.toxlet.2017.08.012. Epub 2017 Aug 24.
• [29] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [30] Induction of cysteine string protein after chronic antidepressant treatment in rat frontal cortex. Neurosci Lett. 2001 Apr 6;301(3):183-6. doi: 10.1016/s0304-3940(01)01638-x.
• [31] The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004 Aug;174(4):525-9. doi: 10.1007/s00213-003-1562-3. Epub 2003 Sep 4.
• [32] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [33] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [34] Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors. Neurochem Res. 2017 Apr;42(4):943-952. doi: 10.1007/s11064-016-2127-2. Epub 2016 Nov 30.
• [35] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [36] A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
• [37] Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
• [38] Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
• [39] In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
• [40] Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
• [41] Drug Interactions Flockhart Table
• [42] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [43] Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004 Dec;24(6):656-60. doi: 10.1097/01.jcp.0000145340.53417.ca.
• [44] Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox. Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):81-5.
• [45] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
• [46] The differential effects of neuroleptic drugs and PACAP on the expression of BDNF mRNA and protein in a human glioblastoma cell line. Acta Neurobiol Exp (Wars). 2017;77(3):205-213.
• [47] The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
• [48] Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 2005;5(5):298-304.
• [49] Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
• [50] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [51] Haloperidol, but not olanzapine, may affect expression of PER1 and CRY1 genes in human glioblastoma cell line. Biol Rhythm Res. 2016 Nov 1;47(6):865-871. doi: 10.1080/09291016.2016.1202379. Epub 2016 Jul 1.
• [52] The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000 Sep;22(9):1085-96. doi: 10.1016/S0149-2918(00)80086-7.
• [53] Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology. 2006 Apr;31(4):853-65. doi: 10.1038/sj.npp.1300911.
• [54] Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells. J Psychiatr Res. 2006 Jun;40(4):374-9. doi: 10.1016/j.jpsychires.2005.04.016. Epub 2005 Jul 5.
• [55] Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
• [56] Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994 Mar;22(1-4):219-26. doi: 10.1016/0169-328x(94)90050-7.
• [57] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [58] Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells. BMC Pharmacol. 2009 Mar 31;9:6. doi: 10.1186/1471-2210-9-6.
• [59] No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
• [60] The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics. 2009 Jun;19(6):437-46. doi: 10.1097/FPC.0b013e32832b9cfc.
• [61] The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett. 2005 May 6;379(2):81-9. doi: 10.1016/j.neulet.2004.12.037. Epub 2005 Jan 26.